Q32 Bio (QTTB) Accounts Payables (2017 - 2026)
Q32 Bio's quarterly Accounts Payables came in at $653000.0 in Q1 2026, down 75.92% year-on-year from $2.7 million in Q1 2025, and down 25.71% quarter-over-quarter from $879000.0 in Q4 2025.
Q32 Bio has reported Accounts Payables for 10 years, with the latest figure at $653000.0 in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables fell 75.92% year-over-year to $653000.0; the trailing twelve-month figure through Mar 2026 stood at $653000.0 (down 75.92% YoY), and the FY2025 full-year result was $879000.0, down 70.59% from the prior year.
- Accounts Payables for Q1 2026 stood at $653000.0, down from $879000.0 in the prior quarter.
- The five-year high for Accounts Payables was $9.9 million in Q1 2022, with the low at $653000.0 in Q1 2026.
- Average Accounts Payables over 5 years is $3.3 million, with a median of $3.0 million recorded in 2024.
- Year-over-year, Accounts Payables jumped 203.15% in 2023 and sank 83.88% in 2024.
- Tracing QTTB's Accounts Payables over 5 years: stood at $1.1 million in 2022, then jumped by 203.15% to $3.5 million in 2023, then dropped by 13.81% to $3.0 million in 2024, then plunged by 70.59% to $879000.0 in 2025, then declined by 25.71% to $653000.0 in 2026.
- The last three Accounts Payables figures came in at $653000.0 (Q1 2026), $879000.0 (Q4 2025), and $973000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | 653,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 653,000.00 |
| Dec 31, 2025 | 879,000.00 |
| Sep 30, 2025 | 973,000.00 |
| Jun 30, 2025 | 910,000.00 |
| Mar 31, 2025 | 2.71 Mn |
| Dec 31, 2024 | 2.99 Mn |
| Sep 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | 2.48 Mn |
| Mar 31, 2024 | 4.96 Mn |
| Dec 31, 2023 | 3.47 Mn |
| Sep 30, 2023 | 7.80 Mn |
| Jun 30, 2023 | 3.39 Mn |
| Mar 31, 2023 | 3.64 Mn |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 4.84 Mn |
| Jun 30, 2022 | 3.76 Mn |
| Mar 31, 2022 | 9.89 Mn |
| Dec 31, 2021 | 2.37 Mn |
| Sep 30, 2021 | 3.52 Mn |
| Jun 30, 2021 | 5.70 Mn |
| Mar 31, 2021 | 4.88 Mn |
| Dec 31, 2020 | 4.72 Mn |
| Sep 30, 2020 | 3.32 Mn |
| Jun 30, 2020 | 7.10 Mn |
| Mar 31, 2020 | 7.40 Mn |
| Dec 31, 2019 | 2.61 Mn |
| Sep 30, 2019 | 8.80 Mn |
| Jun 30, 2019 | 8.33 Mn |
| Mar 31, 2019 | 11.79 Mn |
| Dec 31, 2018 | 15.73 Mn |
| Sep 30, 2018 | 11.12 Mn |
| Jun 30, 2018 | 5.02 Mn |
| Mar 31, 2018 | 3.78 Mn |
| Dec 31, 2017 | 2.54 Mn |